French pharmaceutical giant Sanofi has announced a significant investment of €1 billion to establish a new insulin production base in Beijing. This facility, located in the Yizhuang area, marks the company’s fourth production site in China and represents its largest investment in the country to date. CEO Paul Hudson highlighted that the new facility will feature advanced automated manufacturing technologies and aim to enhance the resilience of the supply chain to meet the growing needs of diabetes patients.